|
|
|
|
|
Highlights from the 2022 European Society of Medical Oncology Annual Meeting |
|
|
|
|
|
Mini Oral Session: GU Tumors, Prostate
|
|
| Quality of Life and Patient-Relevant Endpoints With Darolutamide in the Phase 3 ARASENS Study
|
| Karim Fizazi, MD, Ph.D.
|
| The 2022 European Society of Medical Oncology annual meeting featured a prostate cancer session, including a presentation by Dr. Karim Fizazi discussing quality of life and patient-relevant endpoints with darolutamide in the phase 3 ARASENS study. Early treatment intensification with darolutamide + ADT + docetaxel improved patient-relevant endpoints, with reduced all-cause and prostate cancer related deaths and similar incidences and time course for most adverse events of special interest vs placebo + ADT + docetaxel, notably with no increase in cardiac disorders.
|
|
|
|
|
|
|
|
| Detection of Mutations in Homologous Recombination Repair Genes in Tumour Tissue and Circulating Tumour DNA from Patients with Metastatic Castrate-Resistant Prostate Cancer in the Phase III PROpel Trial
|
| Andrew Armstrong, MD, MSc
|
| In the Prostate Cancer Poster Session of the European Society for Medical Oncology Annual Congress, Andrew Armstrong presented results of an analysis assessing tumor tissue-based and circulating tumor DNA (ctDNA)-based assessment of homologous recombination repair in patients enrolled in the Phase III PROpel trial assessing combination abiraterone and olaparib as first-line treatment in metastatic castrate-resistant prostate cancer.
|
|
|
|
|
|
| Radiographic Progression-Free Survival Correlation with Time-to-Event Endpoints: A Post Hoc Analysis of the VISION Trial |
| Michael Morris, MD |
| Michael Morris presented a post-hoc analysis of the VISION trial aimed at assessing earlier maturing time-to-event endpoints. Dr. Morris concluded that, in this first analysis performed in the context of radioligand therapy, there was a moderate-to-strong correlation between rPFS and OS. Thus, rPFS, as defined by PCWG3, may be relevant as an early endpoint for regulatory approval and clinical trial design in this context. |
|
|
|
|
|
| Biopsy-Based Basal-Luminal Subtyping Classifier in High-Risk Prostate Cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Randomized Phase III Trials |
| Paul Nguyen, MD |
| Paul Nguyen presented an analysis of three NRG Oncology/RTOG clinical trials aimed at assessing the predictive role of basal-luminal subtyping for the duration of androgen-deprivation therapy in high-risk prostate cancer. A gene expression analysis of pretreatment biopsy samples from three NRG phase III trials of high-risk PCa suggests that basal-luminal subtyping is predictive for the benefit of long-term vs short-term ADT. |
|
|
|
|
|
| A Phase 1b Study of a Single Priming Dose of 177Lu-PSMA-617 Coupled with Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
|
| Rahul Aggarwal, MD
|
| Rahul Aggarwal provided preliminary results from a phase 1b study of a single dose of 177Lu-PSMA-617 followed by pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). The approach of a single priming dose of 177Lu-PSMA-617 followed by pembrolizumab demonstrates a favorable safety profile and encouraging anti-tumor activity. Thus, this approach deserves further study.
|
|
|
|
|
|
|
|
|
|
|
| Treatment Patterns and Overall Survival (OS) in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) from 2010 to 2019
|
| Daniel George, MD
|
| Daniel George provided a real-world analysis of treatment approaches in metastatic castration-sensitive prostate cancer (mCSPC). Improvements in overall survival in men treated for mCSPC between 2015 and 2018/19 coincided with the use of treatment intensification in this disease space. However, ongoing underutilization suggests that additional, population-level, survival benefits may be realized.
|
|
|
|
|
|
| Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance
|
| Ashley Ross, MD, Ph.D.
|
| Ashley Ross presented a transcriptome-based assessment of prognostic and predictive biomarkers among patients in the ENACT trial of enzalutamide in patients undergoing active surveillance for prostate cancer. Dr. Ross concluded that biomarker signatures were associated with overall disease progression as well as predictive of the benefit of enzalutamide in patients undergoing active surveillance.
|
|
|
|
|
|
| Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Initial Results from SPLASH
|
| Aaron Hansen BSc, MBBS, FRACP
|
| Aaron Hansen presented the first, preliminary results of the SPLASH trial assessing the radioligand 177Lu-PNT2002 (also known as 177Lu-PSMA I&T) in PSMA-positive patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed after treatment with androgen receptor axis-targeted therapy (ARAT). This first analysis presents the lead-in component of the phase 3 SPLASH trial.
|
|
|
|
|
|
|
|
|
|
|
| Real-World First-Line Treatment Patterns in Patients with High-Risk nmCRPC
|
| Sumati Gupta, MD
|
| The 2022 ESMO annual meeting featured a prostate cancer session, including a presentation by Sumati Gupta discussing real-world first-line treatment patterns in patients with high-risk nmCRPC. This study emphasizes the need for real-world data to help highlight deviations from guidelines and quality metrics. Further studies are needed to assess the obstacles behind treatment intensification in patients with high-risk nmCRPC.
|
|
|
|
|
|
| Treatment Efficacy and Safety of 177Lu-PSMA Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer
|
| Robert Tauber, MD
|
| Robert Tauber discussed the treatment efficacy and safety of 177Lu-PSMA radioligand therapy in octogenarians with mCRPC. Response rates and toxicity of 177Lu-PSMA radioligand therapy in older mCRPC patients are comparable to published data. Chemotherapy-naïve patients showed a better and longer response to therapy than chemotherapy-pretreated patients.
|
|
|
|
|
|
|
